Q3 Earnings Forecast for Prenetics Global Issued By Sidoti

Prenetics Global Limited (NASDAQ:PRE) – Equities researchers at Sidoti lifted their Q3 2026 earnings estimates for Prenetics Global in a research report issued on Wednesday, August 19th. Sidoti analyst A. Hantman now expects that the company will post earnings of ($0.65) per share for the quarter, up from their prior estimate of ($0.85). The consensus estimate for Prenetics Global’s current full-year earnings is ($1.28) per share. Sidoti also issued estimates for Prenetics Global’s Q4 2026 earnings at ($0.62) EPS, FY2026 earnings at ($2.36) EPS, Q1 2027 earnings at ($0.53) EPS, Q2 2027 earnings at ($0.27) EPS, Q3 2027 earnings at ($0.09) EPS and FY2027 earnings at ($0.72) EPS.

A number of other equities analysts also recently issued reports on the company. Wall Street Zen downgraded Prenetics Global from a “hold” rating to a “sell” rating in a research report on Saturday, July 25th. Benchmark boosted their price objective on Prenetics Global from $30.00 to $40.00 and gave the company a “buy” rating in a research report on Wednesday, July 15th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Prenetics Global in a research note on Friday, July 17th. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $34.25.

Prenetics Global Stock Down 4.2%

NASDAQ:PRE opened at $17.97 on Friday. Prenetics Global has a 52 week low of $7.18 and a 52 week high of $23.63. The stock’s 50-day moving average price is $19.08 and its 200-day moving average price is $18.88. The stock has a market capitalization of $303.15 million, a PE ratio of -4.32 and a beta of 0.26.

Prenetics Global (NASDAQ:PRE) last issued its quarterly earnings data on Wednesday, August 19th. The company reported ($0.53) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.84) by $0.31. Prenetics Global had a negative net margin of 47.43% and a negative return on equity of 21.41%. The business had revenue of $46.49 million during the quarter, compared to the consensus estimate of $49.85 million.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. 683 Capital Management LLC purchased a new stake in Prenetics Global during the 4th quarter worth approximately $1,181,000. T3 Companies LLC purchased a new position in shares of Prenetics Global in the fourth quarter valued at approximately $170,000. Kingsview Wealth Management LLC acquired a new stake in shares of Prenetics Global in the fourth quarter worth approximately $172,000. Quadrature Capital Ltd acquired a new stake in shares of Prenetics Global in the fourth quarter worth approximately $468,000. Finally, Boothbay Fund Management LLC purchased a new stake in shares of Prenetics Global during the fourth quarter worth approximately $241,000. Institutional investors and hedge funds own 25.01% of the company’s stock.

Prenetics Global News Summary

Here are the key news stories impacting Prenetics Global this week:

• Positive Sentiment: IM8 reported Q2 2026 revenue growth of 288% year over year and raised its FY 2026 revenue guidance to $220–$230 million. Prenetics also initiated FY 2027 revenue guidance of at least $400 million, signaling management expects rapid growth to continue. IM8 Q2 2026 revenue and guidance article
• Positive Sentiment: Actress and producer Lily Collins will become IM8’s first film-and-television global ambassador and a Prenetics shareholder under a multi-year partnership. Her reach of more than 33 million social-media followers is expected to broaden IM8’s exposure, particularly among female consumers, beyond its existing sports-focused ambassador roster. Lily Collins IM8 partnership article
• Positive Sentiment: Management said IM8 has delivered more than 57 million servings, ships approximately 200,000 servings daily across 46 countries, and generated 54% of revenue outside the United States. Prenetics also reported positive consolidated adjusted free cash flow in July and expects to remain positive through the third quarter and beyond.
• Neutral Sentiment: Analyst estimate changes were mixed: Sidoti modestly raised its Q1 2028 EPS forecast to $0.29 but trimmed its FY 2028 estimate to $2.12, while Zacks lowered its FY 2027 EPS estimate to $1.49 from $1.56. The revisions do not materially change the broader growth narrative.
• Negative Sentiment: The elevated 2026–2027 targets are forward-looking and depend on sustained IM8 demand, successful product launches—including hydration and gummies—and effective marketing. Prenetics remains unprofitable, with consensus estimates calling for a current-year loss of $1.28 per share, leaving execution risk significant.

Prenetics Global Company Profile

Prenetics Global (NASDAQ: PRE) is a molecular diagnostics and genetic testing company that delivers a broad range of laboratory and at-home testing solutions. The company’s core offerings include next-generation sequencing (NGS) panels for hereditary health risks, pharmacogenomic reports to guide medication choices, and comprehensive consumer DNA testing services. In addition to genetic insights, Prenetics provides infectious disease diagnostics—most notably real-time PCR testing for pathogens such as SARS-CoV-2—through an integrated platform that combines sample collection, laboratory processing and digital reporting.

Serving both business-to-consumer and business-to-business markets, Prenetics operates a network of laboratories and service centers across Asia Pacific, Europe, the Middle East and North America.